Westover Capital Advisors LLC Buys New Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Westover Capital Advisors LLC bought a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,483 shares of the company’s stock, valued at approximately $648,000.

Several other institutional investors have also recently added to or reduced their stakes in AMPH. Commonwealth Equity Services LLC increased its stake in shares of Amphastar Pharmaceuticals by 37.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 9,861 shares of the company’s stock valued at $454,000 after acquiring an additional 2,674 shares in the last quarter. Stratos Wealth Partners LTD. bought a new stake in Amphastar Pharmaceuticals in the third quarter valued at $215,000. Shariaportfolio Inc. acquired a new position in shares of Amphastar Pharmaceuticals during the third quarter valued at about $575,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Amphastar Pharmaceuticals by 20.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,436 shares of the company’s stock worth $434,000 after purchasing an additional 1,582 shares in the last quarter. Finally, Mackenzie Financial Corp acquired a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at about $258,000. 65.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Michael A. Zasloff sold 12,500 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the sale, the director now owns 21,326 shares in the company, valued at $1,006,160.68. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 13,500 shares of company stock worth $634,310 over the last quarter. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Stock Up 1.8 %

NASDAQ AMPH traded up $0.75 on Thursday, reaching $42.83. The company had a trading volume of 192,447 shares, compared to its average volume of 445,129. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $2.09 billion, a P/E ratio of 16.31, a P/E/G ratio of 0.99 and a beta of 0.85. The company’s fifty day moving average is $43.89 and its 200 day moving average is $50.82. Amphastar Pharmaceuticals, Inc. has a 52-week low of $35.93 and a 52-week high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, February 28th. The company reported $0.81 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.03). The firm had revenue of $178.11 million during the quarter, compared to analysts’ expectations of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. Sell-side analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on AMPH. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Finally, JPMorgan Chase & Co. began coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $66.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.